Publication Name	World Journal of Hepatology
Manuscript ID	21181
Country	United States

Received	2015-06-30 09:16
Peer-Review Started	2015-07-05 11:01
To Make the First Decision	2015-07-27 15:55
Return for Revision	2015-07-31 11:19
Revised	2015-08-07 03:00
Second Decision	2015-08-25 17:35
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2015-08-31 17:01
Articles in Press	2015-08-31 17:01
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-08-31 19:48
Publish the Manuscript Online	2015-09-09 14:44

ISSN	1948-5182 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Infectious Diseases
Manuscript Type	Minireviews
Article Title	Psychosocial assessment and monitoring in the new era of non-interferon-alpha hepatitis C virus treatments
Manuscript Source	Invited Manuscript
All Author List	Paul J Rowan and Nizar Bhulani
Funding Agency and Grant Number
Corresponding Author	Paul J Rowan, PhD, MPH, Assistant Professor, University of Texas School of Public Health, 1200 Herman Pressler E303, Houston, TX 77030, United States. paul.j.rowan@uth.tmc.edu
Key Words	Depression; Therapy; Psychiatry; Clinical; Direct-acting antivirals
Core Tip	The recently Food and Drug Administration approved direct-acting antiviral regimens for hepatitis C virus (HCV), ledipasvir/sofosbuvir regimen and the ombitasvir/paritaprevir/ritonavir and dasabuvir regimen, have demonstrated great efficacy, and thus far seem to have short treatment timelines and relatively benign side effect profiles. Depression has not emerged as a side effect of these treatments. With efficacious regimens that include no interferon-alpha and no ribavirin, there may no longer be a need for strong psychosocial assessment and monitoring built into the routine of HCV treatment. Good history-taking, strong pharmaceutical review, and reliable consultative relationships should be adequate for meeting psycho-social needs in HCV treatment.
Publish Date	2015-09-09 14:44
Citation	Rowan PJ, Bhulani N. Psychosocial assessment and monitoring in the new era of non-interferon-alpha hepatitis C virus treat­ments. World J Hepatol 2015; 7(19): 2209-2213
URL	http://www.wjgnet.com/1948-5182/full/v7/i19/2209.htm
DOI	http://dx.doi.org/10.4254/wjh.v7.i19.2209

Full Article (PDF)	WJH-7-2209.pdf
Full Article (Word)	WJH-7-2209.doc
Manuscript File	21181-Review.docx
Answering Reviewers	21181-Answering reviewers.pdf
Audio Core Tip	21181-Audio core tip.MP3
Conflict-of-Interest Disclosure Form	21181-Conflict-of-interest statement.pdf
Copyright License Agreement	21181-Copyright assignment.pdf
Signed Informed Consent Form(s) or Document(s)	Informed_Consent_Statement_20150630014353.pdf
Institutional Review Board Approval Form or Document	Institutional_Review_Board_Statement_20150630014339.pdf
Peer-review Report	21181-Peer-review(s).pdf
Scientific Misconduct Check	21181-Scientific misconduct check.pdf
Scientific Editor Work List	21181-Scientific editor work list.pdf